Fate therapeutics announces phase 1 data presentation of ft819 off-the-shelf car t-cell product candidate for sle at eular 2025 congress

Oral presentation of clinical data from ft819 phase 1 study highlights safety and efficacy of fludarabine-free treatment paradigm in moderate-to-severe systemic lupus erythematosus (sle) oral presentation of clinical data from ft819 phase 1 study highlights safety and efficacy of fludarabine-free treatment paradigm in moderate-to-severe systemic lupus erythematosus (sle)
CAR Ratings Summary
CAR Quant Ranking